Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rifampin 600 mg Clear all
Completed Phase 1 Interventional Results available

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

NCT00207090
View directory record Official record
Conditions
Advanced Solid Tumors, Neoplasms
Interventions
ixabepilone, Rifampin
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

NCT02430545
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, Rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 29, 2026, 1:39 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

NCT01068756
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Rifampin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TMC207 +/- Rifabutin/Rifampin

NCT01341184
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifabutin, Rifampin, TMC207
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

NCT03712540
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986278, Rifampin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

NCT03624959
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ozanimod, Gemfibrozil, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast

NCT01561963
View directory record Official record
Conditions
Healthy Subjects
Interventions
Apremilast, Rifampin Oral Capsules, Rifampin IV Solution
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

NCT00405080
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
GW679769 (Casopitant) oral tablets, Rifampin oral capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118

NCT01533870
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
NKTR-118, Rifampin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Results available

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

NCT01324323
View directory record Official record
Conditions
Hematologic Malignancy, Malignant Lymphoma
Interventions
Romidepsin, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 4 Interventional

Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics

NCT03012529
View directory record Official record
Conditions
Osteomyelitis, Diabetes, Amputation
Interventions
Rifampin, Riboflavin Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

NCT01571414
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824, Efavirenz (EFV), Lopinavir/Ritonavir (LPV/r), Rifampin (RIF)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

NCT03301181
View directory record Official record
Conditions
Healthy Volunteers: Asian, Non-Asian
Interventions
BGB-3111 (Arm A), Rifampin, BGB-3111 (Arm B), Itraconazole
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

NCT02046850
View directory record Official record
Conditions
Solid Tumours
Interventions
selumetinib, rifampicin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

NCT01765543
View directory record Official record
Conditions
Malignant Melanoma, Neoplasms
Interventions
Rifampin, Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Rogers, Arkansas • Pleasant Hill, California • Middletown, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

NCT04121078
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buprenorphine Disposition and CYP3A

NCT01576575
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine Control, Buprenorphine + Rifampin, Buprenorphine + Grapefruit juice, Buprenorphine + Ketoconazole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib and Rifampin in Healthy Participants

NCT01908582
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evacetrapib, Rifampin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects

NCT02500667
View directory record Official record
Conditions
Drug Interaction Potentiation
Interventions
N91115, Rifampin
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

NCT03258372
View directory record Official record
Conditions
Healthy
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

NCT06004947
View directory record Official record
Conditions
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

NCT05255276
View directory record Official record
Conditions
Healthy Adults
Interventions
Sitravatinib 50 mg, Sitravatinib 100 mg, Itraconazole, Rifampin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 29, 2026, 1:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

NCT02820935
View directory record Official record
Conditions
Pharmacokinetics
Interventions
CC-220, Rifampin, Itraconazole
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 29, 2026, 1:39 PM EDT